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Abstract
Background: Multidrug resistant tuberculosis (MDR-TB) is a major threat for global tuberculosis control. The W-Beijing
Mycobacterium tuberculosis genotype has been associated with drug resistance. Elucidation of the mechanisms underlying this
epidemiological finding may have an important role in the control of MDR-TB. The aim of this study was to evaluate the fitness
of drug-susceptible and MDR M. tuberculosis strains of the W-Beijing genotype compared with that of Non-W-Beijing strains.
Methodology/Principal Findings: Fitness of M. tuberculosis strains was determined by evaluating the difference in the
growth curves obtained in the MGIT960 automated system and assessing the competitive growth capacity between W-
Beijing and non-W-Beijing strains. The W-Beijing MDR strains had a significant longer lag phase duration compared to the
other strains but did not present a significant fitness cost. When grown in competition they had an advantage only in
medium containing 0.1% Tween 80.
Conclusions/Significance: It was not possible to confirm a selective advantage of W-Beijing strains to grow, except for
differences in their resistance to Tween 80. Further studies are needed to elucidate the putative advantage of W-Beijing
strains compared to other genotypes.
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Introduction
According to the World Health Organization (WHO), there
were globally an estimated 9.27 million new cases of tuberculosis
(TB) and 1.3 million deaths in 2007 [1]. Multidrug resistant
tuberculosis (MDR-TB), caused by Mycobacterium tuberculosis strains
resistant to at least rifampicin (RMP) and isoniazid (INH), is a
major threat for global TB control with direct effect on the
epidemiology of the disease.
Molecular epidemiological tools and genotyping of M. tubercu-
losis strains have identified different families and genotypes
contributing to a better knowledge of the transmission dynamics
of TB and identification of certain genotypes more widespread
than others [2]. The W-Beijing genotype has been strongly
associated with drug resistance in several settings [3–6] and in
regions with high incidence of MDR-TB [7]. The mechanisms
underlying this epidemiological finding have not been clearly
elucidated and its knowledge may have an important role in the
control of MDR-TB.
Some explanations have been advanced but they have not been
conclusive. The W-Beijing genotype could have an enhanced
ability to acquire drug resistance due to a polymorphism in genes
coding for DNA repair enzymes [8]. However, W-Beijing strains
have shown similar rates of mutation-conferring resistance to
RMP compared to non-W-Beijing strains suggesting that they do
not mutate more frequently than non-W-Beijing strains [9]. W-
Beijing strains could offset the physiological cost that would be
expected from the acquisition of drug resistance and thus, spread
in the population with the same efficiency as the susceptible ones.
However, comparison of fitness between in vitro rpoB mutants
showed that W-Beijing and non-W-Beijing strains had similar
biological cost for the same rpoB mutation [10].
Although there are conflicting results between epidemiological
and laboratorial studies, some important experimental findings
have contributed to understand and explain epidemiological
situations. While molecular epidemiological studies have shown
that there is predominance and successful transmission of specific
mutations, such as Ser315Thr in katG and Ser531Leu in rpoB,
associated with MDR M. tuberculosis in several populations
[11–14], laboratorial experiments found that those mutations
cause a lower biological cost in the bacteria [10,15,16].
Furthermore, the fitness was also dependent on the genetic
background of the strain, which can develop compensatory
mutations to mitigate the biological cost [17].
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the genetic background of the strains. This is mainly due to the
limited availability of methods to compare fitness of the bacteria.
In this study we have comparatively evaluated the fitness of drug-
susceptible and MDR M. tuberculosis strains belonging to the W-
Beijing genotype with that of non-W-Beijing strains. Fitness of M.
tuberculosis was determined by different methods that assess the
competitive growth capacity of the strains and evaluate differences
in the growth curves obtained with the MGIT960 automated
system.
Results
Study of fitness by growth curves
As shown in Table 1 four strains were W-Beijing drug susceptible
(Group 1), five strains non-W-Beijing drug susceptible (Group 2),
five strains W-Beijing MDR (Group 3) and five strains non-W-
Beijing MDR (Group 4). We found that the average length of lag
phase for groups 1, 2, 3 and 4 were 148.3 h, 149.7 h, 185.8 h and
154.7 h, respectively (Figure 1A). Group 3 corresponding to W-
Beijing MDR strains presented the longest length of lag phase
(P,0.001). The average rate of growth for groups 1, 2, 3 and 4 was
20.8 h, 22.2 h, 22.9 h and 19.1 h, respectively (Figure 1B) but the
difference was not statistically significant (P=0.462).
Characterization of M. tuberculosis strains selected for
competitive growth
Strains 02-2761 and 03-0265 were confirmed as W-Beijing and
according to SITVIT database [18] had the ST 01 profile; strains
01-2522 and 03-0850 were classified as T1, and strains 01-2522
and 03-0850 had the ST 156 and ST 264 profiles, respectively.
The two MDR strains had the mutation Ser315Thr in katG
associated with resistance to INH and Ser531Leu in rpoB
associated with resistance to RMP.
Fitness studies by competitive growth methodology
Table 2 shows results of the four competition studies with
number and percentage of viable cells before and after
competition and the number of generations (n) for each strain.
The strain 03-0265 (W-Beijing, MDR) had the lowest growth of all
strains (n=3.8) in competition with the strain 02-2761 (W-Beijing,
S), but its growth increased (n=7.4) in competition with the strain
03-0850 (non-W-Beijing MDR). The strain 01-2522 (non-W-
Beijing, S), had a stable and low growth in competition (n=5.2)
with the strain 03-850 (non-W-Beijing MDR) and (n=5.5) with
strain 02-2761 (W-Beijing, S). This strain 02-2761 showed a
growth of n=8.2 and n=11.6 after competition with the strains
03-0265 and 01-2522, respectively. The strain 03-850 (non-W-
Beijing MDR) had a higher growth in competition with strains 03-
0265 (n=14.2) and 01-2522 (n=11.2).
Fitness studies assessed by qPCR
Efficiency of the reaction determined with the nBj and Bj
primers was 1.86 and 1.96, respectively, showing that both had
good efficiency for determination of relative quantification. Table 3
shows the ratio of genomic DNA of the non-W-Beijing strain
compared to W-Beijing. For each test the results show the ratio
found in the starting inoculum (DNA extracted at time 0 of the
competition), the ratio after competition in the presence and
absence of Tween 80 and the ratio of the same strains growing
alone. Test 5 showed that strain 03-0850 (MDR-Non-W-Beijing)
had an inoculum ratio of 6.4 compared to 03-0265 (MDR-W-
Beijing); after competition increased to 14.2 but in the presence of
Tween 80 the ratio was only 2.5. Test 6 showed that strain 01-
Table 1. Study of fitness by growth curve: length of lag phase and rate of growth of each strain.
Strain Number Geographic Origin Genotype by PCR
Profile of
susceptibility
Length of lag
phase
Rate of
growth
Group 1 02-2761 Bangladesh W-Beijing S 152,86 21,23
08-0774 Sweden W-Beijing S 147,50 23,05
09-1051 Argentina W-Beijing S 158,30 17,50
09-1029 Argentina W-Beijing S 134,40 21,54
Group 2 09-0428 Demo Rep Congo non-W-Beijing S 148,50 21,22
01-2522 Georgia non-W-Beijing S 150,46 21,02
09-0168 Demo Rep Congo non-W-Beijing S 158,28 20,19
09-0365 Tanzania non-W-Beijing S 152,70 15,99
09-0009 Demo Rep Congo non-W-Beijing S 138,46 32,77
Group 3 08-1990 Demo Rep Congo W-Beijing MDR 194,64 24,68
03-0265 Bangladesh W-Beijing MDR 174,74 24,13
07-2983 Thailand W-Beijing MDR 190,37 24,54
07-3088 Georgia W-Beijing MDR 187,95 17,25
07-3214 Georgia W-Beijing MDR 181,28 24,02
Group 4 08-1585 Demo Rep Congo non-W-Beijing MDR 156,16 15,78
08-1421 Nigeria non-W-Beijing MDR 157,25 18,02
08-1790 Bangladesh non-W-Beijing MDR 135,34 21,18
03-0850 Georgia non-W-Beijing MDR 168,40 18,79
08-1302 Bangladesh non-W-Beijing MDR 156,55 21,67
S: susceptible to first and second-line drugs tested; MDR: multidrug resistant strain. Demo Rep Congo: Democratic Republic of Congo.
doi:10.1371/journal.pone.0010191.t001
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to strain 02-2761 (S-W-Beijing). After competition the ratio
decreased to 1.7 in 7H9 and in the presence of the Tween 80
the ratio was 0.01. Test 7 showed strain 01-2522 had an inoculum
ratio of 2.8 in relation to strain 03-0265 after competition
decreased to 2.4 in 7H9 and in the presence of Tween 80 the ratio
was 0.01. Test 8 found strain 03-0850 had an inoculum ratio of 5.6
in relation to strain 02-2761 and after competition decreased to
5.1 in 7H9; with Tween 80 the ratio was 0.8.
Discussion
The use of growth curves based on metabolic activity has been
applied before in fitness studies [19,20]. The two parameters here
obtained were the length of lag phase and the rate of growth. The
only significant difference was found for W-Beijing MDR strains
that had a longer lag phase duration. The lag phase is the period
required to adapt to their new environment when actively
synthesizing enzymes to metabolize novel nutrients. The strains
used in this study had few sub-cultures after primary isolation; thus,
it is possible that the resistant strains needed a longer period to
adapt to the new medium without drugs. The rate of growth, was
similar in the four groups studied. It is normally assumed that
MDR strains present a biological cost for growth in the absence of
drugs. The most common mechanism associated with the
acquisition of resistance to RMP is a mutation in the rpoB gene
[21] and for INH are mutations in katG and the inhA operon
[22,23]. These genes encode enzymes of biological significance in
the bacteria, once they mutate, their function could be impaired
leading to a fitness cost. Previous studies have shown that the
biological cost could vary according to the mutation (aminoacid
and position) and the strain genetic background. Also compensa-
Table 2. Viable cells (concentration and percentage) of M. tuberculosis before and after competition assay between resistant and
susceptible strains with the same genotype family.
Profile of
susceptibility Genotype Strain Before competition After competition
Number of
Generation (n)
CFU/mL % CFU/mL %
Test 1 MDR W-Beijing 03-0265 3.86610
4 9.5% 5.2610
5 0.5% 3.8
S W-Beijing 02-2761 3.68610
5 90.5% 10.7610
7 99.5% 8.2
Test 2 MDR Non-W-Beijing 03-0850 2.23610
4 7.0% 5.2610
7 82% 11.2
S Non-W-Beijing 01-2522 2.97610
5 93% 1.11610
7 18% 5.2
Test 3 MDR W-Beijing 03-0265 3.86610
4 63.38% 6.60610
6 1.57% 7.4
MDR Non-W-Beijing 03-0850 2.23610
4 36.32% 4.13610
8 98.43% 14.2
Test 4 S W-Beijing 02-2761 3.68610
5 55.34% 1.11610
9 98.82% 11.6
S Non-W-Beijing 01-2522 2.97610
5 44.66% 1.32610
7 1.17% 5.5
S: susceptible to first and second-line drugs tested; MDR: multidrug resistant strain.
doi:10.1371/journal.pone.0010191.t002
Figure 1. Comparison of the fitness between W-Beijing and non-W-Beijing strains. The length of lag phase (Fig. 1A) and rate of growth
(Fig. 1B) were assessed for strains W-Beijing drug susceptible (Group 1), non-W-Beijing drug susceptible (Group 2), W-Beijing multidrug resistant
(Group 3) and non-W-Beijing multidrug resistant (Group 4). The average length of lag phase for groups 1, 2, 3 and 4 were 148.3 h, 149.7 h, 185.8 h
and 154.7 h, respectively. Group 3 presented the longest length of lag phase compared to the other three groups (P,0.001). The average rate of
growth for groups 1, 2, 3 and 4 was 20.8 h, 22.2 h, 22.9 h and 19.1 h, respectively, but the difference among the groups was not statistically
significant (P=0.462).
doi:10.1371/journal.pone.0010191.g001
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Beijing strains could be more efficient in restoring fitness due to
mutations in DNA repair enzymes, which might provide a selective
advantage [8]. This hypothesis, however, was not confirmed in the
present study by comparison of the growth curves.
Another approach to assess fitness of the bacteria is by their
competitive capacity to grow. Competitive tests are frequently
performed to determine the relative fitness associated with a
specific drug-resistance mutation [24]. This is carried out with one
susceptible and one drug-resistant strain harbouring specific
mutations. After growing in competition in a liquid medium they
are plated in agar with or without antibiotics. The relative fitness is
defined as the ratio of the generation rate between the resistant and
susceptible strain [25]. We adapted this methodology to study the
competitive capacity of W-Beijing and non-W-Beijing strains.
Since both tested strains had the same drug susceptibility profile,
differentiation was not possible by drug selection. We used PCR to
differentiate W-Beijing and non Beijing strains from each colony
obtained after competition. Since all strains belonging to the same
group had similar metabolic activity in the MGIT960 system, we
selected one strain from each group for the competitive study: the
two strains previously classified as W-Beijing by PCR had the
characteristic signature by spoligotyping and the two non-W-
Beijing strains were typed as T1 genotype. Both MDR W-Beijing
and non-W-Beijing strains had the same mutations: Ser531Leu in
rpoB and Ser315Thr in katG. These mutations are the most
frequently found in clinical settings and have also demonstrated a
lower fitness cost in comparison to other mutations for RMP and
INH in experimental studies [10,14–16]. Again, we could not
confirm a selective advantage of the MDR W-Beijing compared to
MDR non-W-Beijing. On the contrary, the MDR non-W-Beijing
strain had a growth advantage in competition. This could be
explained by the growth profile found in MGIT960. Since the
MDR W-Beijing presented a longer lag phase, the longer time to
start growing could be a disadvantage in competition when there
are fewer nutrients available. The intriguing result was the low
efficiency of the non-W-Beijing susceptible strain (02-2522) to
growth in competition. If we analyse its growth in MGIT960 it had
the shortest lag phase and the second highest rate of growth,
however, its growth was unsuccessful in competition. There were
some different factors to consider about growth in competition
related to MGIT960: the strains did not rely only on the capacity
to growth in 7H9 liquid medium, but further on 7H10 agar, the
presence of 0.1% Tween 80 added in 7H9 medium to obtain
homogeneous cell suspensions and the growth in competition with
another strain. To investigate this we performed a new competition
test between W-Beijing and non-W-Beijing strains in the presence
and absence of Tween 80. We applied qPCR to determine relative
quantification of genomic DNA between the two strains before and
after competition. In the presence of Tween 80 strain 02-2522
(susceptible, non-W-Beijing) grew poorly. Tween 80 is an ionic
surfactant used frequently when growing M. tuberculosis in liquid
medium. Effects of surfactants on the mycobacterial cell wall have
been studied before. In M. avium it was found to decrease the
quantity of glycolipids, which are virulent factors, in the cell wall
increasing the permeability of antituberculosis drugs [26]. Different
resistance to Tween among M. tuberculosis strains would be
important to consider not only for its use in mycobacterial
cultures, but related to the relevance of pulmonary surfactants
having an important function as host defence mechanism. If M.
tuberculosis strains have different susceptibility to pulmonary
surfactants, and this could be associated with a specific genotype,
it could represent differences in the cell wall with influence in the
permeability of drugs or virulence factors.
Taken together these results show that it was not possible to
confirm a selective advantage of W-Beijing strains to grow, except
for differences in their resistance to Tween 80. These results reflect
what occurs in vitro, being in this way limited to reproduce the in
vivo interaction between pathogen and the host. Further studies of
W-Beijing strains associated to pulmonary surfactants could give
new insights for understanding factors inherent to the pathogen
inside the host that could influence the course of the disease.
Materials and Methods
Study design
The study was performed in three phases: phase I involved
comparison of fitness between W-Beijing and non-W-Beijing strains
performing growth curves using the MGIT960 system; phase II
studied fitness by assessing the competition between W-Beijing and
non-W-Beijing strains by viable cell counting; and phase III
assessed the competitive fitness using Real-Time PCR (qPCR).
Strains
Nineteen M. tuberculosis strains of the W-Beijing and non-W-
Beijing genotype with different drug susceptibility profiles were
Table 3. Ratio of the DNA genomic determined by qPCR between the strains non-W-Beijing in relation to W-Beijing before and
after competition.
Profile of
susceptibility Genotype Strain
Inoculum
Ratio 7H9 7H9 + Tween
Competition
ratio
Alone
growth ratio
Competition
ratio
Alone growth
ratio
Test 5 MDR Non-W-Beijing 03-0850 6.4 14.2 3.2 2.5 0.4
MDR W-Beijing 03-0265
Test 6 S Non-W-Beijing 01-2522 2.1 1.7 6.7 0.01 0.002
S W-Beijing 02-2761
Test 7 S Non-W-Beijing 01-2522 2.8 2.4 7.5 0.01 0.004
MDR W-Beijing 03-0265
Test 8 MDR Non-W-Beijing 03-0850 5.6 5.1 2.7 0.8 0.85
S W-Beijing 02-2761
S: susceptible to first and second-line drugs tested; MDR: multidrug resistant strain.
doi:10.1371/journal.pone.0010191.t003
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performed by a polymerase chain reaction (PCR) assay previously
described [27]. Drug susceptibility profile was determined by the
proportion method according to standard procedures [28]. From
the 19 strains, four were selected for the competitive fitness studies,
one strain each of W-Beijing-MDR, W-Beijing drug susceptible,
non-W-Beijing-MDR, and non-W-Beijing drug susceptible.
Strains were fully characterized and analyzed for the presence of
mutations conferring resistance to RMP and INH. Spoligotyping
was performed with a commercial kit (Ocimum Biosolutions BV,
India) according to standard procedures [29].
Molecular characterization
Genomic DNA was obtained by resuspending a loopful of culture
into 200 ml of TE buffer (10 mM Tris-HCl, 1 mM EDTA pH 8.0)
heat-inactivated at 100uC for 10 min and centrifuged for 20 min at
10,000 x g at 4uC. DNA sequencing was performed to look for
mutations in rpoB, katG and the inhA promoter associated with
resistance to RMP and INH, respectively. Sequencing of rpoB was
performed as previously described [30]. For INH the primers were
TB86/TB87 to amplify katG and TB92/TB93 for the inhA promoter
[31]. The PCR product was sequenced with an automatic DNA
sequencer (Applied Biosystems 3730 DNA analyzer). The ClustalX
program (version 1.83.1) and Genedoc software (version 2.100) were
used to analyze the final nucleotide sequences.
Phase I: Fitness studies by growth curve using the
MGIT960 system
All strains were freshly subcultured on Lo ¨wenstein Jensen
medium and incubated at 37uC for exactly 3 weeks. The inoculum
was prepared by suspending bacilli in 4 ml ultra-pure water
containing glass beads. The suspension was vortexed for 30 s and
allowed to sediment for 15 min. The supernatant was transferred
to another tube, diluted to match the turbidity of a McFarland
tube No. 0.5 and adjusted at 595 nm to an OD of 0.01–0.03. A
dilution 1:10 was prepared in ultra-pure water. One hundred mlo f
this dilution was added in triplicate to MGIT Mycobacteria
Growth Indicator Tubes (Becton Dickinson Diagnostic Systems,
Sparks, MD, USA) supplemented with 10% MGIT960 SIRE
TM
Supplement (Becton Dickinson, USA). The tubes were entered into
the MGIT960 system and incubated at 37uC. Growth curves were
obtained by monitoring the fluorescence and recording the growth
units (GU) every hour using the BD EpiCenter
TM software.
Growth parameters
The fitness of each strain was compared by two parameters
from the growth curves: the length of the lag phase and the rate of
growth. The length of lag phase was determined from the start of
incubation until reaching 75 GU (positive threshold in MGIT960).
The rate of growth was the time in hours necessary for a strain to
increase from 5,000 to 10,000 GU in the MGIT960 system. It was
calculated from the growth curve considering that all strains were
in the logarithmic phase of growth between these two points.
Differences in these two parameters were calculated with
ANOVA and Student-Newman-Keuls tests for all pairwise
comparisons with the MedCal
TM software (v9.6.2.0; Mariakerke,
Belgium). It was considered significant if P,0.05.
Phase II: competitive fitness determined by viable cell
counting
In this experiment, the drug-susceptible and drug-resistant W-
Beijing and Non-W-Beijing M. tuberculosis strains competed in a
common environment.
Four selected M. tuberculosis strains: 03-0265 (W-Beijing-MDR),
02-2761 (W-Beijing-drug susceptible), 03-0850 (Non-W-Beijing-
MDR) and 01-2522 (Non-W-Beijing - drug susceptible) were
freshly subcultured on Lo ¨wenstein Jensen medium and incubated
at 37uC. A bacterial suspension was transferred into separate tubes
containing 5 mL of 7H9 medium (Middlebrook 7H9 medium with
0.1% casitone, 0.5% glycerol, 10% OADC (oleic acid, albumin,
dextrose and catalase) (Becton-Dickinson, USA) and 0,1% Tween
80 and incubated at 37uC for 20 days. The turbidity of each tube
was adjusted according to the less concentrated tube and further
diluted 10
21 and 10
22.
Pairwise competition was performed as follows according to
previously described methodology [25] tube 1, 03-0265 (W-
Beijing-MDR) and 02-2761 (W-Beijing-drug susceptible); tube 2,
03-0850 (Non-W-Beijing-MDR) and 01-2522 (Non-W-Beijing -
drug susceptible); tube 3, 03-0265 (W-Beijing-MDR) and 03-0850
(Non-W-Beijing-MDR); and tube 4, 02-2761 (W-Beijing-drug
susceptible) and 01-2522 (Non-W-Beijing - drug susceptible). Each
tube contained 4 mL of 7H9 medium, 0.1% Tween 80, 50 mLo f
the inoculum diluted 10
21 for the susceptible strains and 50 mlo f
the inoculum diluted 10
22 for the MDR strains. The number of
viable cells in the inocula was estimated according to Miles and
Misra [32]. Tubes were incubated at 37uC and after 17 days the
number of colony forming units (CFU) in each tube was
determined by plating serial 10-fold dilutions in Middlebrook
7H10 agar with or without RMP at 5 mg/ml for tube 1 (W-
Beijing-MDR + W-Beijing-S) and tube 2 (Non-W-Beijing-MDR +
Non-W-Beijing-S). CFUs in tube 3 (W-Beijing-MDR + Non-W-
Beijing-MDR) and tube 4 (W-Beijing-S + Non-W-Beijing-S) was
determined by plating serial 10-fold dilutions in Middlebrook
7H10 agar without RMP. All plates were incubated at 37uC. After
4 weeks the number of CFU of the drug-susceptible strain was
calculated by subtracting the number of CFUs of the drug-
resistant from the total number of CFU. For tubes 3 and 4 to
differentiate and calculate the number of W-Beijing CFU from the
non-W-Beijing CFU each colony was sub-cultured in Middlebrook
7H9 liquid medium and then, a PCR with specific primers for
identification of the W-Beijing and non-W-Beijing genotypes was
performed [27]. In order to compare the growth of each strain in
competition, the number of generations was determinate using the
formula:
n~log Nf ðÞ   log N0 ðÞ =log2
Whereas: n = number of generation; N0= initial number of
viable cells; Nf= final number of viable cells;
Phase III. Competitive fitness quantified by qPCR
In this experiment, the fitness of W-Beijing and Non-W-Beijing
strains with the same drug-susceptibility profile was assessed by
qPCR.
The inoculum was prepared as described above for the phase II
studies. The competition was performed in two sets of 8 tubes
containing 5 ml of 7H9 medium with (set one) or without (set two)
0.1% Tween 80. Tube 1: 50 ml each of 03-0265 (W-Beijing-MDR)
and 03-0850 (Non-W-Beijing-MDR); tube 2: 50 mL of 02-2761
(W-Beijing-drug susceptible) and 01-2522 (Non-W-Beijing - drug
susceptible); tube 3: 50 mL of 03-0265 (W-Beijing-MDR) and 01-
2522 (Non-W-Beijing - drug susceptible); tube 4: 50 mL of 02-2761
(W-Beijing-drug susceptible) and 03-0850 (Non-W-Beijing-MDR);
tube 5: 50 ml of 03-0265 (W-Beijing-MDR); tube 6: 50 ml of 03-
0850 (Non-W-Beijing-MDR); tube 7: 50 mL of 02-2761 (W-
Beijing-drug susceptible); and tube 8: 50 mL 01-2522 (Non-W-
Fitness of M. tuberculosis
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time 0 and incubated at 37uC for 30 days. One ml from each tube
was used for DNA extraction after sedimentation at 5,000 x g
for10 min and the pellet resuspended in Lysis Extraction Solution
(50 mM Tris HCl pH 7.5, 10 mM EDTA, 0.5% SDS, 50 mM
NaCl, 300 mg/mL Proteinase K). Purification was performed with
chloroform-amyl alcohol (24:1) and precipitation with 3 M
Sodium Acetate and 500 mL of absolute ethanol. The DNA
precipitate was washed with 75% ethanol and suspended in 50 mL
of ultra pure water.
The relative quantification of W-Beijing and non-W-Beijing
strains was performed by qPCR according to Hillemann et al.
[33]. For each sample, two reactions were performed in triplicate,
the first with primers nBjF: 59-AAGCATTCCCTTGACAGTC-
GAA-39 and nBjR: 59-GGCGCATGACTCGAAAGAAG-39 to
quantify the non-W-Beijing strain and the second with primers
BjF59-CTCGGCAGCTTCCTCGAT-39 and BjR59-CGAACT-
CGAGGCTAGCCTACTAC-39 to quantify W-Beijing. The
reaction was performed in a final volume of 10 mL consisting of
1x QuantiTect SYBR Green PCR Kit (Qiagen), 0.33 mMo f
forward and reverse primers and 1 mL of a 1:100 dilution of DNA.
PCR was run in a LightCyclerH 480 Real-Time PCR System
(Roche) at 95uC for 15 min, 40 cycles of 95uC for 15 s, 55uC for
20 s, 72uC for 30 s and for the melting curve 95uC 5 s, 70uC
1 min 95.
DNA extracted from strains 03-0265 (W-Beijing) and 03-0850
(non-W-Beijing) were diluted 1:2, 10
21,1 0
22,1 0
23,1 0
24,1 0
25
and 10
26 and tested in triplicate to determine the efficiency of the
primers Bj and NBj. For determining the relative fitness, the
LightCyclerH 480 software calculated the proportion between the
W-Beijing strain and non-W-Beijing taking into account the
efficiency of the primers and the Threshold Cycle (TC) obtained
for each strain in each reaction.
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